Literature DB >> 30740414

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Shih-Feng Cho1,2,3, Kenneth C Anderson1, Yu-Tzu Tai1.   

Abstract

Entities:  

Year:  2018        PMID: 30740414      PMCID: PMC6330615          DOI: 10.21037/atm.2018.11.14

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  21 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

3.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

4.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

5.  Zoom Zoom: racing CARs for multiple myeloma.

Authors:  Marcela V Maus; Carl H June
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

6.  Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.

Authors:  Scott E James; Nural N Orgun; Thomas F Tedder; Mark J Shlomchik; Michael C Jensen; Yukang Lin; Philip D Greenberg; Oliver W Press
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

7.  B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Authors:  Robert O Carpenter; Moses O Evbuomwan; Stefania Pittaluga; Jeremy J Rose; Mark Raffeld; Shicheng Yang; Ronald E Gress; Frances T Hakim; James N Kochenderfer
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

8.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

Authors:  C Imai; K Mihara; M Andreansky; I C Nicholson; C-H Pui; T L Geiger; D Campana
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

Review 9.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

10.  Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.

Authors:  Herschel Wallen; John A Thompson; J Zachary Reilly; Rebecca M Rodmyre; Jianhong Cao; Cassian Yee
Journal:  PLoS One       Date:  2009-03-09       Impact factor: 3.240

View more
  3 in total

1.  Potential factors of specialists' willingness to write editorial and commentary: a retrospective study based on 5,091 invitations.

Authors:  Hengrui Liang; Lujiao Ye; Wenhua Liang; Runchen Wang; Fan Ge; Lihua Fan; Yao Zhu; Grace S Li; Stephen D Wang; Kevin Phan; Alan Sihoe; Kaiping Zhang; Jianxing He
Journal:  Ann Transl Med       Date:  2019-12

Review 2.  B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

Authors:  Nina Shah; Ajai Chari; Emma Scott; Khalid Mezzi; Saad Z Usmani
Journal:  Leukemia       Date:  2020-02-13       Impact factor: 11.528

3.  Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.

Authors:  Haobin Deng; Meijing Liu; Ting Yuan; Huan Zhang; Rui Cui; Jingyi Li; Jijun Yuan; Xiaofang Wang; Yafei Wang; Qi Deng
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.